ArticlePharmaceuticals (Basel, Switzerland)2026
Evolution of Multitarget Strategies for Alzheimer's Disease: From Cholinergic Inhibition to Network-Oriented Therapeutic Design (2006-2025).
Jaime Mella, Alejandro Vega-Muñoz, Mauricio Soto, Daniel Moraga, Javier Campanini-Salinas, Eduardo Sandoval-Obando, Nicolás Contreras-Barraza, Guido Salazar-Sepúlveda, Natalia Salas-Guzmán, Remik Carabantes-Silva and 1 more
Abstract read
In one paragraphArticle in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Jaime MellaInstituto de Química, Facultad de Ciencias, Universidad de Valparaíso, Valparaíso 2360102, Chile.ORCID 0000-0002-2434-8461 Alejandro Vega-MuñozLaboratorio de Bienestar y Comportamiento Organizacional, Facultad de Medicina y Ciencias de la Salud, Universidad Central de Chile, Santiago 8330507, Chile.ORCID 0000-0002-9427-2044 Mauricio SotoDepartamento de Química, Universidad Técnica Federico Santa María, Av. España 1680, Valparaíso 2340000, Chile.ORCID 0009-0001-1864-7561 Daniel MoragaLaboratorio de Fisiología, Departamento de Ciencias Biomédicas, Facultad de Medicina, Universidad de Tarapacá, Arica 1000000, Chile.ORCID 0000-0002-7128-8174 Javier Campanini-SalinasEscuela de Química y Farmacia, Facultad de Ciencias, Universidad San Sebastián, Puerto Montt 5501842, Chile.ORCID 0000-0002-7358-409X Eduardo Sandoval-ObandoEscuela de Psicología, Facultad de Ciencias Sociales y Humanidades, Universidad Autónoma de Chile, Temuco 4800916, Chile.ORCID 0000-0001-7471-6536 Nicolás Contreras-BarrazaFacultad de Ciencias Económicas y Administrativas, Pontificia Universidad Católica de Valparaíso, Valparaíso 2340025, Chile.
Guido Salazar-SepúlvedaFacultad de Ingeniería, Universidad Católica de la Santísima Concepción, Concepción 4090541, Chile.ORCID 0000-0002-4979-6869 Natalia Salas-GuzmánFacultad de Educación y Ciencias Sociales, Universidad Finis Terrae, Santiago 7501015, Chile.ORCID 0000-0001-8815-5979 Remik Carabantes-SilvaFacultad de Ciencias Naturales, Matemáticas y del Medio Ambiente, Universidad Tecnológica Metropolitana, Santiago 8330383, Chile.ORCID 0000-0002-9592-5203 Funding
Central University of Chile Puente de Investigación UCEN Convocatoria Año 2025 grant CIPPTE202505
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Alzheimer’s diseaseblood–brain barrierdrug discoverymultitarget-directed ligands (MTDLs)network pharmacologyoxidative stressβ-amyloid aggregation
Identifiers
PMID42515707
PMCPMC13415210
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390